GBA Presents: RADIO SAVANT-!

Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences
September 03, 2020 06:59 AM Eastern Daylight Time


CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following virtual investor conferences in September:

  • Citi 15thAnnual BioPharma Virtual Conference on Thursday, September 10, 2020
  • Goldman Sachs 10thAnnual Biotech Symposium on Friday, September 11, 2020
  • H.C. Wainwright 22ndAnnual Global Investment Conference on Monday, September 14, 2020; presentation at 1:00 p.m. ET
  • Cantor Global Healthcare Conference on Wednesday, September 16, 2020; presentation at 9:20 a.m. ET
  • Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Monday, September 21, 2020; presentation at 10:50 a.m. ET
 
TOUCHDOWN!

I will be buying MGNX before the conference-!



MacroGenics to Participate in Upcoming Investor Conferences
September 02, 2022 07:00 ET| Source:MacroGenics, Inc.



ROCKVILLE, MD, Sept. 02, 2022 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in September 2022:

  • Citi 17thAnnual BioPharma Conference (Boston).MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in the Bispecific Panel on Wednesday, September 7, 2022, at 2:40 pm ET. Management will also participate in one-on-one meetings.
  • H.C. Wainwright 24thAnnual Global Investment Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D. will provide a corporate overview on Monday, September 12, 2022, at 10:30 am ET. MacroGenics’ management will also participate in one-on-one meetings.
  • Guggenheim Nantucket Therapeutics Conference.MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on September 28, 2022, at 2:30 pm ET and participate in one-on-one meetings.
Webcasts of the above will be made available under “Events & Presentations” in the Investor Relations section of MacroGenics’ website athttp://ir.macrogenics.com/events.cfm. The Company maintains archived replays of webcasts on its website for 30 days after the conference.

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website atwww.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###
 
WTF!

Man who jumped from 18th floor of NYC tower identified as Bed Bath & Beyond CFO
Gustavo-Arnal-image-courtesy-linkedin-account-1019x573.jpg

clock.png



By CNBCTV18.com Sep 04, 2022, 03:32 PM IST (Published)
Mini
The incident occurred just two days after Bed Bath & Beyond announced plans to shut 150 of its roughly 900 stores and lay off 20 percent of its staff.


The man, who jumped from the 18th floor of the 'Jenga' tower in Manhattan, New York, on September 2, has been identified as Gustavo Arnal, the Chief Financial Officer of Bed Bath & Beyond, an US-based chain of retail stores, according to multiple reports.
 
You must log in or register to reply here.
Back
Top